Researchers developed a novel compound to target prostate cancer using radioactive atom astatine-211, potentially overcoming issues with previous compounds like deastatination. The study found high accumulation in tumors and low accumulation in vital organs, highlighting the potential of this new compound for targeted alpha therapy.
SourceChiba University·JournalEJNMMI Radiopharmacy and Chemistry·TypeExperimental study·DateSep 3, 2024
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Aston University researcher has developed a new method of analysing crystals in dehydrated blood samples using polarisation-based image reconstruction technique. The technique showed a 90% accuracy rate for early diagnosis and classification of cancer, making it less traumatic and risky for patients.
SourceAston University·JournalScientific Reports·TypeExperimental study·DateSep 2, 2024
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
SourceFlinders University·JournalBritish Journal of Cancer·TypeRandomized controlled/clinical trial·DateSep 1, 2024
Researchers investigated the connection between androgen deprivation therapy for prostate cancer and Alzheimer's disease. They found that ADT can exacerbate cognitive decline by increasing brain immune cell infiltration, but a combination with Natalizumab improved integrity of the blood-brain barrier and reduced inflammation.
SourceMedical College of Georgia at Augusta University·JournalScience Advances·DateAug 29, 2024
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
SourceJohns Hopkins Medicine·JournalJAMA Oncology·DateAug 22, 2024
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
SourceKarolinska Institutet·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateAug 20, 2024
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
Researchers at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles that could revolutionize how cancer and other diseases are diagnosed. These molecules undergo changes when cancer is present, suggesting their potential as biomarkers for detecting prostate cancer.
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of Extracellular Vesicles·TypeExperimental study·DateAug 16, 2024
A new study suggests that MRI scans can help doctors identify patients with more aggressive prostate cancer, allowing for earlier treatment or active surveillance. The research found that suspicious lesions on an MRI test were associated with a higher risk of advanced disease in five years.
SourceCorewell Health·JournalThe Journal of Urology·DateAug 7, 2024
A new deep learning model detects clinically significant prostate cancer on MRI with performance comparable to experienced abdominal radiologists. The model's prediction can be used as an adjunct to improve diagnostic performance and reduce false positives.
SourceRadiological Society of North America·JournalRadiology·DateAug 6, 2024
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
Researchers have developed an AI-based system that can predict the risk of prostate cancer more accurately than traditional methods. The new tool combines MRI images and deep learning to identify low-risk patients who may not need a biopsy, potentially sparing them from unnecessary procedures and reducing complications.
SourceGerman Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)·JournalEuropean Journal of Radiology·DateAug 5, 2024
Researchers from the University of Sheffield have developed a new form of immunotherapy using nanoparticles that delays the onset of resistance to hormone therapy in prostate cancer. This innovative approach stimulates immune cells called T cells to attack cancer cells, marking a significant breakthrough in treating prostate cancer.
SourceUniversity of Sheffield·JournalBMJ·TypeExperimental study·DateAug 5, 2024
Researchers highlight acute need for mental health services and support for men with prostate cancer. The study found that 15% of prostate cancer patients started anti-anxiety and antidepression medications at diagnosis, while only 6% sought help from mental health services.
SourceUniversity of South Australia·TypeData/statistical analysis·DateAug 4, 2024
Nikon Monarch 5 8x42 Binoculars
Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
SourceMichigan Medicine - University of Michigan·JournalCancer Cell·TypeExperimental study·DateJul 30, 2024
A recent review article highlights the importance of genetic testing for men carrying BRCA1 or BRCA2 mutations, which increase their risk of developing prostate, pancreatic, and breast cancers. The guidelines emphasize the need for personalized cancer screening to help identify high-risk individuals.
SourceFred Hutchinson Cancer Center·JournalJAMA Oncology·TypeLiterature review·DateJul 26, 2024
Researchers at UCLA Health Sciences identified three distinct patient preference-based profiles among men with low-risk prostate cancer. Despite differences in preferences, physician recommendations played a crucial role in determining treatment choices. The study highlights the need for better integrating patient preferences into trea...
SourceUniversity of California - Los Angeles Health Sciences·JournalUrology Practice·DateJul 25, 2024
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Researchers found that lower doses of radiopharmaceutical therapy approaches for metastatic castrate-resistant prostate cancer were just as effective as the standard dose, with better tolerability among patients. The study showed improved PSA response rates and comparable median overall survival in both groups.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJul 24, 2024
A recent study published in Journal of Clinical Oncology has shown that the Stockholm3 prostate cancer blood test is equally effective in detecting clinically significant cancer across different ethnic groups, including African Americans and Asians. The test reduces unnecessary biopsies by 45% while maintaining high detection rates.
SourceKarolinska Institutet·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJul 23, 2024
Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.
SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateJul 17, 2024
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Researchers found that out-of-pocket costs for additional tests, including MRI and biopsies, are common and increasing among privately insured men with high PSA results. The median cost rose substantially between 2010-2020, deterring patients from undergoing recommended screening.
A study found that living in disadvantaged neighborhoods is associated with higher stress-related gene activity, which could contribute to aggressive prostate cancer in African American men. The research also linked five genes related to inflammation to an increased risk of prostate cancer.
SourceUniversity of Maryland School of Medicine·JournalJAMA Network Open·TypeObservational study·DateJul 12, 2024
A cross-sectional study found that men from disadvantaged neighborhoods had higher stress-related gene expression in their prostate tumors. This association suggests a potential link between neighborhood factors and aggressive prostate cancer.
SourceJAMA Network·JournalJAMA Network Open·DateJul 12, 2024
Researchers identified two risk factors that indicate higher risk of aggressive prostate cancer, including high PSA levels and positive biopsy samples. Patients with these indicators are at increased risk of adverse pathology, early recurrence, and death.
SourceMass General Brigham·JournalEuropean Urology Oncology·TypeObservational study·DateJul 9, 2024
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
Researchers developed a novel liquid biopsy technique to monitor disease evolution in metastatic prostate cancer patients. The method analyzes DNA and RNA in circulating extracellular vesicles, capturing tumor genomics and transcriptomic changes.
SourceVall d'Hebron Institute of Oncology·JournalCancer Cell·DateJul 8, 2024
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant to advance personalized cancer therapy for prostate cancer patients. They aim to predict and prevent long-term side effects from radiation treatment, improving quality of life for men diagnosed with the disease.
SourceUniversity of California - Los Angeles Health Sciences·DateJul 3, 2024
Pharmacogenomics (PGx) testing can predict how patients will respond to systemic therapies, enabling personalized treatment plans and optimizing medication dosages. A specific gene variant, HSD3B1, has been linked to castration-resistant prostate cancer progression.
SourceXia & He Publishing Inc.·JournalExploratory Research and Hypothesis in Medicine·DateJul 2, 2024
Researchers at Osaka University have developed molecules that can correct improper splicing of a vital tumor suppressor gene in neuroendocrine cancers. The study demonstrates that these splice-switching oligonucleotides can significantly reduce viable cancer cells and tumor size in mice, suggesting a novel therapeutic approach for intr...
SourceOsaka University·TypeExperimental study·DateJul 2, 2024
Garmin GPSMAP 67i with inReach
Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.
A new study has identified potential cancer drivers hidden in so-called 'junk' regions of DNA, which could lead to early diagnosis and new treatments. The discovery reveals mutations in previously overlooked regions of the genome that may contribute to the formation and progression of at least 12 different cancers.
SourceGarvan Institute of Medical Research·JournalNucleic Acids Research·TypeExperimental study·DateJul 2, 2024
A phase 2 study found fluorine-18 PSMA-1007 PET/computed tomography to be superior to multiparametric MRI for locoregional staging of prostate cancer. The technology supports its use in the preoperative workflow for intermediate-risk and high-risk tumors.
SourceJAMA Network·JournalJAMA Oncology·DateJul 1, 2024
Researchers explore the feasibility of deep learning models in segmenting lesions on PET/CT images to improve salvage radiation therapy planning for prostate cancer. The study demonstrates promising potential to reduce inter- and intra-observer variations, leading to more accurate treatment outcomes.
SourceImpact Journals LLC·JournalOncoscience·TypeCommentary/editorial·DateJun 28, 2024
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
A recent study published in JAMA found that transgender women on hormone therapy have drastically lower PSA levels, which may lead to delayed diagnosis and treatment of prostate cancer. The researchers analyzed Veterans Health Administration records and recommended caution when interpreting PSA values in transgender women.
SourceUniversity of California - San Francisco·JournalJAMA·DateJun 28, 2024
Current prostate cancer screening guidelines may not be effective for transgender women taking estrogen, as it can lower PSA levels, making it difficult to detect early-stage cancer. The study aims to provide more appropriate screening guidelines for this population.
SourceCedars-Sinai Medical Center·JournalJAMA·TypeMeta-analysis·DateJun 26, 2024
Xiaohu Xia's research focuses on enhancing diagnostic efficacy of enzyme-linked immunosorbent assay (ELISA) testing using specially tailored nickel-platinum nanoparticles. His goal is to improve disease detection accuracy by more than 300 times, enabling early diagnosis of cancers like prostate and colorectal cancer.
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
Scientists have identified a new mechanism by which cells counteract a key cancer-promoting protein using an 'invisible' protein called RAI2. In cancer cell lines and patient samples, RAI2 levels are reduced in more severe and treatment-resistant forms of prostate cancer.
SourceEuropean Molecular Biology Laboratory·JournalNature Communications·TypeExperimental study·DateJun 19, 2024
Ternarx aims to unlock the potential of targeted protein degrader (TPD) technology to treat hard-to-treat cancers like neuroblastoma and prostate cancer. The company will initially focus on developing new treatments for these diseases using novel TPD technology.
A recent study published in The Lancet Oncology found that an AI system can detect prostate cancer nearly seven percent more significantly than a group of radiologists using MRI scans. Additionally, the AI identifies suspicious areas less often, potentially reducing unnecessary biopsies by half.
SourceRadboud University Medical Center·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateJun 12, 2024
A new AI model has been shown to significantly improve the accuracy of diagnosing prostate cancer by 45 times compared to doctors' measurements alone. The system assists in mapping out the boundaries of cancerous tissue, reducing the risk of underestimation and enabling more precise treatment planning and effective surgical procedures.
SourceUniversity of California - Los Angeles Health Sciences·JournalThe Journal of Urology·DateJun 11, 2024
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
A new chelator, L804, reduces off-target toxicity in PSMA radiopharmaceutical therapy by improving the bond between radioactive metal ions and targeting antibodies. This makes the therapy safer and more effective for patients.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 11, 2024
A glowing marker dye attached to a special marker molecule enables surgeons to visualize prostate cancer cells in real-time, allowing for more precise removal of cancerous tissues and preservation of healthy tissue. This technology has the potential to reduce the chances of cancer recurrence and minimize life-changing side effects.
SourceCancer Research UK·JournalEuropean Journal of Nuclear Medicine and Molecular Imaging·TypeExperimental study·DateJun 9, 2024
[177Lu]Lu-PSMA-617 significantly improves radiographic progression-free survival and overall quality of life for patients with taxane-naive mCRPC, while minimizing adverse events. The study's findings suggest that [177Lu]Lu-PSMA-617 may change the treatment paradigm for pre-taxane advanced prostate cancer patients.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 9, 2024
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
SourceImpact Journals LLC·JournalOncoscience·TypeCommentary/editorial·DateJun 7, 2024
Researchers identified protein JUN as a potential therapeutic option to slow tumor growth in prostate cancer, contradicting previous findings that linked high JUN levels to increased tumor growth. The study showed that JUN slows tumor progression and improves immune response, providing a new starting point for therapy development.
SourceMedical University of Vienna·JournalMolecular Cancer·DateJun 5, 2024
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
This population-based study found that higher PSA screening prevalence was associated with lower odds of advanced disease and prostate cancer-specific mortality among men with prostate cancer. Associations varied by age, race and ethnicity, and U.S. Census region.
SourceJAMA Network·JournalJAMA Network Open·DateJun 4, 2024
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.
SourceJAMA Network·JournalJAMA Oncology·DateJun 3, 2024
A cost-effectiveness analysis found that first-line MRI-based screening for prostate cancer is less effective and more costly than first-line PSA testing. Despite free MRI costs, the first-line approach resulted in increased false positives and overdiagnosis without substantial reductions in mortality.
SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateJun 3, 2024
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
Researchers found that increased activity of the SIX2 protein contributes to increased cell plasticity and treatment resistance in prostate cancer cells. Silencing the SIX2 gene reduces malignancy and cancer spread in hormone therapy-resistant types of cancer.
SourceUniversity of Eastern Finland·JournalNucleic Acids Research·DateJun 3, 2024
Pharmaceutical genomic testing can optimize drug dosages and minimize adverse events in treating metastatic prostate cancer. By understanding an individual's genetic variations, clinicians can tailor treatments more effectively.
SourceXia & He Publishing Inc.·JournalExploratory Research and Hypothesis in Medicine·DateMay 31, 2024
Active surveillance for favorable-risk prostate cancer demonstrated to be a safe and effective management strategy, with less than 2% developing metastatic disease. The study found no significant association between delayed treatment during surveillance and worse outcomes.
A new alpha-ray therapeutic agent ([At-211] PSMA-5) has been developed to target prostate-specific membrane antigen (PSMA) in refractory prostate cancer patients. The therapy has shown efficacy in animal models and is now being tested in a first-in-human clinical trial.
SourceOsaka University·TypeRandomized controlled/clinical trial·DateMay 27, 2024
A study analyzing data from the National Cancer Database found that patients receiving care at minority-serving hospitals were 17% less likely to receive definitive treatment for breast cancer and up to 31% less likely for prostate, lung, and colon cancers. Improving treatment rates could lead to additional patient outcomes.
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
A genomic study of over 5,000 veterans with advanced prostate cancer reveals significant differences in frequencies of alterations associated with race and ethnicity. Alterations in immunotherapy targets were more common in Black veterans, potentially leading to opportunities for precision-based therapy.
SourceUniversity of California - Los Angeles Health Sciences·DateMay 24, 2024
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
A recent Australian study found that 20% of prostate cancer patients were over-treated, receiving surgery despite limited life expectancy. The study suggests that cancer risk stratification is a primary determinant of treatment choices, with low-risk patients more likely to have active surveillance.
SourceXia & He Publishing Inc.·JournalCancer Screening and Prevention·DateMay 22, 2024
Researchers found that miR-377 reduces MYC mRNA levels, leading to increased Bax and PTEN expression and decreased CDK4. This results in induced apoptosis, inhibited proliferation, and arrested cell cycle in prostate cancer cells.
SourceImpact Journals LLC·JournalGenes & Cancer·TypeExperimental study·DateMay 21, 2024
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
SourceJohns Hopkins Medicine·JournalCancer Immunology Research·DateMay 21, 2024
A new questionnaire assesses sexual health concerns in female partners of prostate cancer patients, highlighting challenges with communication and feelings of isolation. The study reveals high levels of distress and depression among these women.
SourceNYU Langone Health / NYU Grossman School of Medicine·JournalEuropean Urology Oncology·TypeSurvey·DateMay 20, 2024
The American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting will be held in Washington, D.C., featuring over 170 exhibitors showcasing state-of-the-art cancer care technologies. Registered attendees can access livestreams of scientific and educational sessions, both in-person and virtually.
SourceAmerican Society for Radiation Oncology·DateMay 16, 2024
A new study suggests that longer screening intervals for prostate cancer are safe and effective when the initial PSA test is conducted at a young age. The PROBASE trial found that only 0.45% of men with low-risk PSA levels developed high PSA levels, indicating an increased risk of prostate cancer. This finding supports the idea of rais...
SourceGerman Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)·JournalEuropean Urology·TypeObservational study·DateMay 16, 2024
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
A plant-based diet is associated with a 47% lower risk of prostate cancer progression in men. Eating one or two extra servings of healthy foods daily can significantly reduce the disease's worsening chances.
SourceUniversity of California - San Francisco·JournalJAMA Network Open·DateMay 13, 2024
New cancer projections highlight progress in reducing incidence rates for common cancers like lung, colorectal, and prostate, but also warn of rising rates for less common types such as liver, kidney, melanoma, and non-Hodgkin lymphoma.
SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeData/statistical analysis·DateMay 13, 2024